医院内感染市场规模、份额和成长分析（按类型、治疗方法、感染类型、最终用户和地区）- 产业预测 2025-2032

2023 年全球医院内感染市场规模价值 304 亿美元，预计将从 2024 年的 308.6 亿美元成长到 2032 年的 347.6 亿美元，预测期内（2025-2032 年）的复合年增长率为 1.5%。

由于人们对医院内感染（HAI）认识的不断提高、预防交叉感染的迫切需求以及医疗机构中感染疾病爆发的不断增加，感染控制市场正在经历强劲增长。灭菌设备、清洗和消毒剂、防护屏障和内视镜再处理工具等关键产品在最大限度地减少医院内感染方面发挥关键作用。此外，政府倡导改善感染控制措施的支持措施进一步加强了该产业的发展。医院、地方和国家层级采用全面的感染预防指南以及提高监测技术的整合度是推动市场扩张的关键因素。随着认知和依从性的提高，对有效感染控制产品和服务的需求只增不减，这使得这成为一个充满活力且重要的市场。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

医院感染市场规模（按类型和复合年增长率）（2025-2032）

• 市场概况
• 装置
  • 灭菌设备
  • 消毒设备
• 耗材
  • 消毒剂
  • 灭菌耗材
  • 其他的
• 服务

医院感染市场规模（依治疗方法及复合年增长率） (2025-2032)

• 市场概况
• 抗菌
• 抗病毒药物
• 抗真菌
• 其他的

医院感染市场规模（按感染类型和复合年增长率） (2025-2032)

• 市场概况
• 血流感染疾病
• 人工呼吸器相关性肺炎 (VAP)
• 尿道感染
• 手术部位感染
• 胃肠道感染疾病
• 其他的

医院感染市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院和诊所
• 门诊手术中心
• 其他的

医院感染市场规模（依地区划分）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• STERIS plc（Ireland）
• Getinge AB（Sweden）
• 3M（USA）
• Ecolab Inc.（USA）
• Diversey Holdings, Ltd.（USA）
• Roche Holding AG（Switzerland）
• Abbott Laboratories（USA）
• bioMerieux SA（France）
• Thermo Fisher Scientific Inc.（USA）
• Becton, Dickinson and Company（BD）（USA）
• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• Novartis AG（Switzerland）
• GlaxoSmithKline plc（UK）
• Sanofi SA（France）
• Medtronic plc（Ireland）
• Cardinal Health（USA）
• Johnson & Johnson（USA）

结论和建议

Global Hospital-Acquired Infections Market size was valued at USD 30.4 billion in 2023 and is poised to grow from USD 30.86 billion in 2024 to USD 34.76 billion by 2032, growing at a CAGR of 1.5% during the forecast period (2025-2032).

The infection control market is witnessing robust growth driven by heightened awareness of Hospital Acquired Infections (HAIs), the urgent need to combat cross infections, and the rising prevalence of infectious diseases within healthcare facilities. Key products such as sterilization equipment, cleaning and disinfection agents, protective barriers, and endoscope reprocessing tools play crucial roles in minimizing hospital-acquired infections. Additionally, supportive government initiatives advocating for improved infection control measures further bolster this sector. The adoption of comprehensive infection prevention guidelines at hospital, regional, and national levels, along with the growing integration of monitoring technologies, are significant factors fueling market expansion. As awareness and compliance grow, the demand for effective infection control products and services continues to rise, making this a dynamic and vital market space.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hospital-Acquired Infections market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hospital-Acquired Infections Market Segmental Analysis

Global Hospital-Acquired Infections Market is segmented by Type, Treatment, Infection Type, End User and region. Based on Type, the market is segmented into Equipment, Consumables and Services. Based on Treatment, the market is segmented into Antibacterial, Antiviral, Antifungal and Others. Based on Infection Type, the market is segmented into Bloodstream Infections, Ventilator-Associated Pneumonia (VAP), Urinary Tract Infection, Surgical-Site Infection, Gastrointestinal Infections and Others. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hospital-Acquired Infections Market

The Global Hospital-Acquired Infections market is poised for growth driven by the rising number of surgical procedures performed globally. According to the World Health Organization, approximately 235 million major surgeries are carried out annually, a trend fueled by the increasing prevalence of obesity, lifestyle-related diseases, an aging population, and a surge in spine and sports injuries. As more surgeries take place, the demand for surgical tools and medical devices escalates. The recognized advantages of sterilized equipment, coupled with heightened awareness of their importance in healthcare environments, are expected to significantly boost the demand for services addressing hospital-acquired infections.

Restraints in the Global Hospital-Acquired Infections Market

The growth of the Global Hospital-Acquired Infections market is hindered by apprehensions surrounding the safety of reprocessed medical instruments. While reusing devices like surgical forceps, endoscopes, and stethoscopes can significantly reduce costs and environmental waste for healthcare providers, doubts persist regarding the efficacy and cleanliness of these reprocessed items. Improper cleaning and sterilization processes might leave behind blood, tissue, and other biological residue, elevating the risk of surgical-site infections (SSIs) and hospital-acquired infections (HAIs). Furthermore, any residual materials, such as chemical disinfectants, could lead to tissue irritation. This uncertainty is resulting in limited acceptance of device reprocessing among hospital administrators and clinicians.

Market Trends of the Global Hospital-Acquired Infections Market

The Global Hospital-Acquired Infections (HAIs) market is experiencing significant growth, propelled by a surge in chronic diseases like diabetes, cardiovascular disorders, and gastrointestinal conditions. With environmental and lifestyle factors contributing to rising disease prevalence-projected to escalate from 537 million diabetics in 2021 to approximately 783 million by 2045-there will be an uptick in surgical procedures, consequently elevating the risk of HAIs. Increased awareness and need for stringent sterilization and disinfection protocols will further drive demand for infection control devices. As such, the market is poised for robust expansion, addressing both the rise in surgical interventions and the necessity for enhanced infection prevention measures.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hospital-Acquired Infections Market Size by Type & CAGR (2025-2032)

• Market Overview
• Equipment
  • Sterilization Equipment
  • Disinfection Equipment
• Consumables
  • Disinfectants
  • Sterilization Consumables
  • Others
• Services

Global Hospital-Acquired Infections Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Antibacterial
• Antiviral
• Antifungal
• Others

Global Hospital-Acquired Infections Market Size by Infection Type & CAGR (2025-2032)

• Market Overview
• Bloodstream Infections
• Ventilator-Associated Pneumonia (VAP)
• Urinary Tract Infection
• Surgical-Site Infection
• Gastrointestinal Infections
• Others

Global Hospital-Acquired Infections Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Global Hospital-Acquired Infections Market Size & CAGR (2025-2032)

• North America (Type, Treatment, Infection Type, End User)
  • US
  • Canada
• Europe (Type, Treatment, Infection Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Infection Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Infection Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Infection Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• STERIS plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getinge AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 3M (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ecolab Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diversey Holdings, Ltd. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations